Opioid Addiction/Pregnancy and Neonatal Abstinence Syndrome (NAS)

A Preliminary Open-Label Study of Buprenorphine Maintenance and Drug Use Targeted Psychotherapy (Dust) on Cessation of Addictive Drug Use

Datos Bibliográficos

ID15519142
AutoresSarah Tabi (SUNY Upstate Medical University), Sarah A Heitner (SUNY Upstate Medical University), Swati Shivale (Bellevue Hospital Center), Scott B Minchenberg (0000-0002-0445-5956, Beth Israel Deaconess Hospital), Scott Minchenberg, Stephen V Faraone (0000-0002-9217-3982, SUNY Upstate Medical University), Brian Johnson (0000-0001-9122-172X, SUNY Upstate Medical University, autor de correspondencia)
Año2020
Volumen11
Páginas563409-563409
Fecha de publicación2020-09-23
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaFrontiers in Psychiatry (JOURNAL)
Identificadores de la revistaISSN: 1664-0640 • E-ISSN: 1664-0640
EditorialFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2020.563409
PMID33173512
OpenAlexW3089255298
IdiomaEN
Citas recibidas2
Referencias citadas18

This preliminary open-label case series found that pregnant buprenorphine maintained women can stop tobacco. What has sometimes been termed "neonatal opioid abstinence syndrome" may most accurately be termed, "neonatal opioid/tobacco abstinence syndrome." If the treatment effectively addresses tobacco use, other addictive drugs are rarely used. DUST resulted in a 95% quit rate for addictive drugs. Pilot data on this new intervention is limited; a case series that does not have a corresponding control group

Abstinence · Addiction · Buprenorphine · Drug · Heroin · Intervention (counseling · Opioid · Opioid use disorder · Pregnancy · Psychiatry · Substance abuse · Maternal Mental Health During Pregnancy and Postpartum · Medicine · Neuroscience of respiration and sleep · Prenatal Substance Exposure Effects · Internal Medicine